Clinical trials: Resistant BRCA Wild-Type Ovarian Cancer
Ovarian Cancer
Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected
The objective of this study was to evaluate the efficacy and safety of alpelisib in combination with olaparib compared with single-agent cytotoxic chemotherapy in participants with platinum-resistant or platinum-refractory…
- Trial name
- NCT04729387
- Testing
- Alpelisib, Olaparib, Paclitaxel
- Where
- 93 sites in United States, Argentina and 24 more
- Volunteers
- 358 people
- Sponsor
- Novartis Pharmaceuticals
Ovarian Neoplasm Epithelial, High Grade Serous Carcinoma
Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Patients
This study is a phase II clinical trial to evaluate the safety and efficacy of Bortezomib plus Pegylated liposomal doxorubicin combination therapy in a histologic type of high-grade serous carcinoma without BRCA mutation among…
- Trial name
- NCT03509246
- Testing
- Pegylated liposomal doxorubicin plus Bortezomib
- Where
- South Korea
- Volunteers
- 44 people
- Sponsor
- Seoul National University Hospital
Ovarian Cancer, Resistant BRCA Wild-Type Ovarian Cancer
CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer Patients
The purpose of this protocol is to investigate the efficacy of the combination of CB-839 with Niraparib in platinum resistant BRCA wild-type ovarian cancer patients.
- Trial name
- BRCA (NCT03944902)
- Testing
- Cohort 1: Dose Escalation, Cohort 2: Dose Escalation
- Where
- 4 sites in United States
- Volunteers
- 1 people
- Sponsor
- University of Alabama at Birmingham
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma
Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer
This phase I/II trial tests the safety, side effects and best dose of a combination therapy (niraparib and selenium) in treating patients with BRCA negative ovarian cancer that has come back (recurrent) and does not respond to…
- Conditions
- Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma
- Trial name
- NCT05672095
- Testing
- Biopsy, Biospecimen Collection, Niraparib
- Sponsor
- City of Hope Medical Center